Laboratory Diagnostics for Hepatitis C Virus Infection

Size: px
Start display at page:

Download "Laboratory Diagnostics for Hepatitis C Virus Infection"

Transcription

1 SUPPLEMENT ARTICLE Laboratory Diagnostics for Hepatitis C Virus Infection Saleem Kamili, Jan Drobeniuc, Aufra C. Araujo, and Tonya M. Hayden Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia Identification of prevalent infection by hepatitis C virus (HCV) is based serologically on detecting anti-hcv immunoglobulin G, using immunoassays, immunoblot assays, and, more recently, immunochromatographybased rapid tests. None discriminate between active and resolved HCV infection. Tests for detecting HCV RNA identify active HCV infection but are costly. Serologic assays for HCV antigens have been developed and show potential for diagnosis of active HCV infection, and their performance characteristics are undergoing evaluation. The diagnosis of acute HCV infection without the demonstration of seroconversion remains elusive. Hepatitis C virus (HCV) is a positive-strand RNA virus belonging to the Hepacivirus genus in the family Flaviviridae [1]. Its 9.6-kb-long viral genome is flanked by 2 untranslated regions at its 5 and 3 ends and contains a single open reading frame that encodes a polyprotein of approximately 3000 amino acids. The polyprotein is cleaved into 10 single proteins by a host signal peptidase in the structural region and by viralencoded proteases in the nonstructural region. Structural proteins, which form the viral particle, include the core protein and the envelope glycoproteins E1 and E2. Nonstructural proteins include the p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B proteins. Owing to robust viral replication, an estimated 10 trillion virion particles can be produced per day during the active phase of infection [2]. HCV isolates are classified into 6 genotypes that differ in their nucleotide sequence by 30% 35% and into multiple subtypes that differ in their nucleotide sequence by 20% 25% [3]. Genotypes 1a and 1b are the most prevalent genotypes Received 26 January 2012; accepted 23 March Correspondence: Saleem Kamili, PhD, Centers for Disease Control and Prevention, National Center for HIV/Hepatitis/STD/TB Prevention, Division of Viral Hepatitis, 1600 Clifton Rd NE, Mailstop A-33, Atlanta, GA (skamili@cdc.gov). Clinical Infectious Diseases 2012;55(S1):S43 8 The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please journals.permissions@oup.com. DOI: /cid/cis368 in the United States and western Europe, followed by genotypes 2 and 3. By contrast, genotype 4 is common in Egypt, genotype 5 in South Africa, and genotype 6 in Southeast Asia. Following the cloning of the HCV genome, antigenic regions and B-cell epitopes were identified [4]. Recombinant proteins and synthetic peptides containing these immunodominant epitopes were used as antigens in immunodiagnostic assays, leading to the development of commercially available screening and supplemental assays for anti-hcv immunoglobulin G (IgG) [5, 6]. Recently, a rapid anti-hcv IgG assay was approved by the Food and Drug Administration (FDA) for clinical use in the United States [7]. These assays, however, cannot identify whether an antibodypositive person has active HCV infection, since anti- HCV IgG may be detectable in persons who have resolved infection and are no longer viremic. Nucleic acid testing (NAT) for the detection of HCV RNA remains the gold standard for diagnosing active HCV infections. However, the laboratory setup for performing NAT requires expert technical staff, expensive equipment and reagents, dedicated procedure areas, and availability of pristine serum or plasma samples. Because of these requirements, NAT is not routinely performed in many clinical laboratories. Availability of a serologic assay not based on NAT but indicative of active infection should further facilitate identification of HCV-infected patients and enable referral to care. A Diagnostics of HCV Infection CID 2012:55 (Suppl 1) S43

2 serological assay based on the detection of HCV core antigen has shown promise in this regard [8]. This review will focus on the challenges in the field of HCV diagnostics, novel technologies being developed for rapid and reliable serological and molecular assays, and efforts to develop assays for distinguishing acute from chronic HCV infection. DETECTION OF ANTI-HCV IgG Immunoassays A number of immunoassays have been developed to detect anti-hcv IgG in serum or plasma specimens. First-generation assays were based on a yeast-expressed recombinant protein containing an epitope from the NS4 region (C100-3) of the HCV genome. Although these assays identified anti-hcv IgG in approximately 80% of patients with posttransfusion hepatitis and led to the substantial reduction in transfusion-associated HCV infections, they lacked sensitivity and specificity [9]. Second- and third-generation assays used a multiantigen format and included antigens from the core, NS3, and NS4 regions (Figure 1); these modifications markedly improved sensitivity and specificity [6]. The difference between the second- and third-generation assays is the inclusion of an additional antigen from the NS5 region [10]. These assays reduced the window period observed in first-generation assays by an average of 5 weeks and permitted anti-hcv to be detected as early as 10 weeks after exposure. The diagnostic specificity of third-generation assays is >99% [11]. Nonetheless, third-generation enzyme immunoassays (EIAs) can yield false-negative results in patients who are undergoing hemodialysis or who are immunocompromised [12]. Furthermore, these assays can yield low positive predictive values among populations with a low (<10%) prevalence of HCV infection [13]. False-positive results can have unintended consequences for the tested person, resulting in psychological harm and unnecessary medical visits. The US Centers for Disease Control and Prevention (CDC) recommended that a person be considered to have serologic evidence of HCV infection if a positive result of anti-hcv screening is confirmed by positive results of a further test, using either a recombinant immunoblot antibody assay (RIBA) or NAT to detect HCV RNA. However, despite these recommendations, reflex supplemental testing has not been widely performed by many laboratories for various reasons, which include complexity of the assays, long turnaround time of test results, and high cost. The CDC issued another set of guidelines that expand earlier recommendations by including an option to use signal-to-cutoff ratios to limit the number of samples needing supplemental testing [14]. These guidelines were based on a study of serum samples (n = ) from US populations with an anti-hcv IgG prevalence ranging from 0.8% to 25%, using FDAlicensed or approved anti-hcv screening kits (enzyme-linked or chemiluminescence immunoassays), RIBA, and NAT. The study established specific signal-to-cutoff ratios for several assays that predicted a true antibody positive result >95% of the time, regardless of the anti-hcv prevalence or characteristics of the population tested [14]. The evaluated assays and their specific signal-to-cutoff ratios are listed in Table 1. It is important to note that these signal-to-cutoff ratios are assay specific and cannot be applied to assays that have not been evaluated. Recombinant Immunoblot Assays RIBAs such as RIBA-3 (Chiron) and strip immunoblot assays, including INNO-LIA Ab III (Innogenetics), DECISCANT HCV (Sanofi-Pasteur), and Lia Tek HCV (Organon), are intended for use as additional, more specific tests for detection of anti-hcv IgG in serum or plasma specimens that have been found reactive in anti-hcv screening assays. Detection of anti-hcv by RIBA is based on immobilization of HCV recombinant antigens and synthetic peptides from core, NS3, and NS5 proteins (Figure 1) as individual bands onto a Table 1. Signal-to-Cutoff Ratios Established for Food and Drug Administration Approved, Commercially Available Screening Assays for Detecting Anti Hepatitis C Virus Immunoglobulin G Assay Manufacturer Method Ratio Figure 1. Locations of hepatitis C virus (HCV) encoded antigens and peptides used in anti-hcv immunoassays and recombinant immunoblot assays. Abbreviations: CIA, chemiluminescence immunoassay; EIA, enzyme immunoassay; RIBA, recombinant immunoblot antibody assay; UTR, untranslated region. Ortho HCV Version 3.0 EIA Ortho EIA (manual) 3.8 Abbott HCV EIA 2.0 Abbott EIA (manual) 3.8 VITROS Anti-HCV Ortho CIA (automated) 8.0 AxSYM Anti-HCV Abbott MEIA (automated) 10.0 ARCHITECT Anti-HCV Abbott CMIA (automated) 5.0 Advia Centaur HCV Siemens CIA (automated) 11.0 Ratios are predictive of true-positive results >95% of the time. Abbreviations: CIA, chemiluminescence immunoassay; CMIA, chemiluminescent microparticle immunoassay; EIA, enzyme immunoassay; MEIA, microparticle enzyme immunoassay. S44 CID 2012:55 (Suppl 1) Kamili et al

3 membrane. Reactivity with 2 proteins indicates a positive result; the test result is considered to be indeterminate if reactivity to only 1 protein is detected. Indeterminate results may be due to nonspecific cross-reacting antibodies or indicative of recent infection that has not yet triggered a broad humoral response. In HCV-infected individuals, assay results are generally indeterminate during the first week of infection and become fully positive 1 6 months later [15]. False-negative RIBA results may be observed in immunocompromised patients or in individuals who have resolved infection in whom anti-hcv levels are waning [14]. The advantages of RIBAs are that they are serologic assays and can be performed on the same sample used in the screening assay and that they are highly specific. However, these assays are not amenable to routine use, in view of their relative decreased sensitivity, high cost, hands-on complexity, and long duration of the procedure. Furthermore, a true-positive RIBA result only indicates the presence of anti-hcv and may reflect past infection with spontaneous clearance; confirmation of active infection still requires testing for HCV RNA. Rapid Assays Despite the excellent sensitivity and specificity of third-generation EIAs, the turnaround time for reporting test results is at least 1 day, thereby making it difficult to deliver the results to tested individuals at first visit. Rapid tests are formatted such that they do not require complicated instrumentation or testing by skilled technical staff. They potentially generate results within an hour and therefore may be used for pointof-care testing. The CDC recently completed evaluation of 3 rapid tests for detecting anti-hcv IgG (Orasure, Chembio, and Medmira) in laboratory and field settings. These assays, which are based on recombinant antigens derived from core, NS3, NS4, and NS5 proteins in an immunochromatographic format, were found to exhibit a high specificity of >99%, with sensitivity ranging from 86% to 99% [7, 16]. The OraQuick HCV Rapid Antibody Test for the detection of anti-hcv IgG was recently approved by the FDA for use with fingerstick, whole-blood, and venous blood specimens from individuals aged 15 years and at risk for infection with HCV and from persons with signs and symptoms of hepatitis. The test also received an FDA waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) [17]. Since facilities that can perform CLIA-waived tests outnumber the laboratories performing screening EIAs, the test has the potential to be used far more widely, such as in physician offices, outreach clinics, and community-based organizations. Rapid tests are typically more expensive than conventional immunoassays and are not designed for testing large batches of specimens. However, in nonclinical settings and laboratories that conduct low-volume testing, adoption of rapid testing can be cost-effective. CDC guidelines formulated for confirming screening anti-hcv results remain to be refined to accommodate rapid anti-hcv testing. It is important to emphasize that OraQuick HCV test has not been approved for general screening. A positive result of a rapid anti-hcv positive test is indicative of the presence of anti-hcv and, again, does not indicate active infection. DETECTION OF VIRUS-SPECIFIC MOLECULES NATs for HCV RNA Detection HCV RNA is detectable in serum or plasma as early as 1 week after exposure and therefore remains the most reliable marker and gold standard for diagnosis of active HCV infection [18]. NATs currently in routine use for detecting HCV RNA are based on polymerase chain reaction (PCR), branched DNA signal amplification, and transcriptionmediated amplification. Qualitative and quantitative PCR assays for HCV RNA testing that have been approved for clinical use by regulatory authorities in the United States and Europe are listed in Table 2. With the advent of ultrasensitive quantitative NATs that have a broad dynamic range and can detect as little as 5 IU/mL of HCV RNA, the use of qualitative methods is expected to decline. Until 1997, HCV RNA titers measured by different quantitative NATs were expressed in different units. The development of an international HCV RNA standard by the World Health Organization provided a common standard unit of measurement, the international unit (IU) [19], which is now used in all commercial assays. All NATs exhibit high specificities of up to 99% across all 6 genotypes of HCV. The availability of ultrasensitive quantitative NATs combined with reporting of viral titers in similar unitage across different assays has been crucial for effectively monitoring response to therapy during anti-viral treatment of HCV infected patients. In addition to NATs for qualitative and quantitative HCV RNA, assays for HCV genotyping are also available; these are based variously on direct sequencing, reverse hybridization to genotype-specific oligonucleotide probes, and restriction fragment length polymorphism analysis [18]. HCV genotyping has clinical applications, since infection by certain genotypes is associated with differential outcomes of treatment, which currently are based on interferon and ribavirin [20]. Immunoassays for HCV Core Antigen The HCV core or nucleocapsid protein is a phosphoprotein of 191 amino acids in length. Antigenic characterization showed the potential of HCV core antigen as a diagnostic marker, and several assays that rely on detecting the presence of the HCV core antigen alone or in combination with anti-hcv in serum Diagnostics of HCV Infection CID 2012:55 (Suppl 1) S45

4 Table 2. Qualitative and Quantitative Hepatitis C Virus RNA Assays Available for Clinical Use Assay Manufacturer Method Lower Limit of Detection, a (Dynamic Range) IU/mL Qualitative Amplicor HCV v2.0 Roche RT-PCR (manual) 50 COBAS Amplicor HCV v2.0 Roche RT-PCR (semiautomated) 50 Ampliscreen b Roche RT-PCR (semiautomated) <50 Versant HCV RNA Gen-Probe TMA (manual) 10 UltraQual HCV RT-PCR National Genetics RT-PCR 10 Procleix HIV-1/HCV b Gen-Probe TMA (manual) <50 Quantitative Amplicor HCV Monitor Roche RT-PCR (manual) 50 ( ) COBAS Amplicor HCV Monitor v2.0 Roche RT-PCR (semiautomated) 50 ( ) Versant HCV RNA 3.0 Siemens bdna (semiautomated) 615 ( ) COBAS Ampliprep/TaqMan Roche qpcr (semiautomated) 18 ( ) Real Time HCV/m2000sp/m2000rt Abbott qpcr (semiautomated) 12 ( ) HCV SuperQuant National Genetics RT-PCR (semiautomated) 20 ( ) LCx HCV RNA-Quantitatie b Abbott RT-PCR (manual) 25 ( ) Abbreviations: bdna, branched DNA; qpcr, quantitative polymerase chain reaction; RT-PCR, reverse-transcription polymerase chain reaction; TMA, transcription-mediated amplification. a Dynamic ranges are specified in parentheses. b Used for blood screening only. or plasma have been developed [21 23]. A quantitative antigen assay, the Architect HCV Ag assay (Abbott), is now commercially available in Europe. It adopts an automated platform and is a chemiluminescence-based immunoassay in which microparticles are coated with a monoclonal antibody to the HCV core antigen [21]. Detection of HCV core antigen within the first 2 weeks of acute infection has been reported in studies involving blood donors. It has been shown to have a sensitivity ranging from 80% to 99% and a specificity ranging from 96% to 100%. A 100% sensitivity in the window period of infection has also been reported in other studies involving blood donors [8]. Although the assay has been shown to have equivalent sensitivity across all HCV genotypes, detection of genotype 1 (1 pg/ml HCV core antigen = 8000 IU/mL HCV RNA) is slightly better than genotype 3 (1 pg/ml HCV core antigen = 6711 IU/mL of HCV RNA) [8]. The advantages of the HCV core antigen assay are that it is an immunoassay, it does not require sample processing as in molecular assays, and a positive result confirms active infection. One limitation of the HCV core antigen assay is that it has a lower sensitivity than NAT; its lower limit of detection is approximately 1000 IU/mL of HCV RNA. The Architect HCV Antigen assay is not yet commercially available in the United States. Emerging Technologies for HCV Detection Recent advances in molecular technologies have produced promising new tools that have the potential for use in the development of new and improved assays for the diagnosis of HCV infection. Prototype nanoparticle-based diagnostic assays have been developed for detection of biomarkers in various diseases, including hepatitis C. The most commonly used nanoparticles are quantum dots (QDs) and gold nanoparticles [24]. QDs are nanoparticles made of semiconductor materials that emit light upon excitation at different spectra, depending on their size, which greatly increases the ability to multiplex [25]. A sensitivity of 1 ng/ml was achieved in a biochip-based assay in which a QD-conjugated RNA oligonucleotide probe targeted the HCV NS5B [26]. A multiplex platform using a microfluidic chip and antigen-coated QDs embedded in polystyrene beads has been reported to detect antibodies to HBV, HCV, and HIV with a sensitivity in the picomolar range [27, 28]. Gold nanoparticles, usually 2 50 nm in size, have been successfully used in various assay formats to detect anti-hcv, as well as HCV RNA [29]. Among other novel technologies currently being evaluated for their diagnostic potential in HCV infections is the use of aptamers as capture molecules. Aptamers are short, singlestranded oligonucleotides that can fold into specific 3-dimensional structures and recognize target molecules such as small chemicals, proteins, and even cells [30]. They have been used for various diagnostic applications because of their ability to bind their targets with high affinity and specificity. Furthermore, these molecules are generated by an in vitro selection process, which eliminates the need for generation of S46 CID 2012:55 (Suppl 1) Kamili et al

5 antibodies in vivo [31]. The role of these molecules in the detection of HCV antigen has been described in preliminary reports [32, 33]. A novel amplification method, loop-mediated isothermal amplification (LAMP), has the potential to be developed into a point-of-care NAT for HCV RNA detection [34 36]. HCV RNA has been reported to be successfully amplified, to a sensitivity of 8 copies/ml. A device that integrates the LAMP methodology on microfluidic chips has been described and is reported to be capable of completing amplification in an hour, using <1 μl of sample, with a sensitivity of 10 fg/µl [37]. These various promising technologies await further evaluation. DISTINGUISHING ACUTE FROM CHRONIC HCV INFECTION People who are recently infected by HCV tend to respond better to antiviral therapy than those who are chronically infected [12]. This consideration drives efforts to identify recent or acute HCV infection. An ideal approach to the diagnosis of acute HCV infection is either the demonstration of seroconversion in a patient found at first testing to be positive for HCV RNA or of progression to HCV RNA-positive status in a patient with a recent history of exposure to HCV infection. These approaches are possible for closely monitored select populations such as intravenous drug users who regularly attend a healthcare or needle-exchange center or individuals who have recently been exposed to well-defined risk events, like a needlestick injury or receipt of an HCV-infected organ transplant [38]. The majority of the patients are, however, already positive for HCV RNA and anti-hcv at presentation, so identification of whether the patient is in the early or acute phase of infection is seldom possible. Unlike acute hepatitis B virus infection, in which immunoglobulin M (IgM) antibody to the hepatitis B core antigen is diagnostic of acute infection and precedes the appearance of IgG, for HCV infection the IgM antibody responses are variably detected in both acute and chronic phases [39]. Anti-HCV IgM cannot therefore serve as a diagnostic marker of acute HCV infection. As such, no IgM anti-hcv assays are licensed for clinical use. In the absence of an IgM anti-hcv assay, various alternative approaches have been explored to distinguish acute from chronic HCV infection. These include monitoring viral load fluctuations [40] or variations in HCV antibody titers [41] and determination of the avidity of IgG antibody to HCV [42, 43]. One such anti-hcv IgG avidity assay is based on use of a mixture of recombinant HCV core, NS3, and NS4 antigens. Evaluation of its performance by use of seroconversion panels suggests that it is potentially possible to reliably discriminate acute from chronic HCV infection [44]. A multiplexed immunoassay to detect anti-hcv IgG reactivities to several HCV antigens simultaneously has been developed and used to correlate reactivities with the stage of HCV infection. In a preliminary proof-of-principal study, testing of seroconversion panels and samples from chronically infected blood donors showed a progressive increase in the anti-hcv IgG antibody titers to the antigens as the infection progressed [45]. These promising assays require further evaluation and validation in various clinical settings. CONCLUSIONS Serologic testing for prevalent HCV infection based on anti- HCV IgG has become more robust and refined. With the introduction of rapid formats for anti-hcv testing, an even broader base of populations at risk of HCV infection can now be screened with a view to identifying infected individuals for referral to care and treatment. NATs for detecting HCV RNA remain the mainstay for discriminating between people who are actively infected and those who have resolved infection. Immunoassays for HCV core antigen detection can limit the use of costly and labor-intensive NATs. The NATs would need to be reformatted and marketed to be more amenable to point-of-care testing and more affordable. Notes Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Financial support. The Viral Hepatitis Action Coalition of the Centers for Disease Control and Prevention Foundation receives support from the following corporate sponsors: Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Janssen Therapeutics, Merck Sharp & Dohme, OraSure Technologies, and Vertex Pharmaceuticals. Supplement sponsorship. This article was published as part of a supplement entitled The Evolving Paradigm of Hepatitis C, sponsored by an unrestricted grant from the Viral Hepatitis Action Coalition of the CDC Foundation. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. References 1. Thiel HJ. Virus taxonomy. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. VIIIth Report of the International Committee on Taxonomy of Viruses. Waltham, Massachusetts: Academic Press, 2005: Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: Lin HJ, Lau JY, Lauder IJ, Shi N, Lai CL, Hollinger FB. The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. Virus Res 1993; 30: Diagnostics of HCV Infection CID 2012:55 (Suppl 1) S47

6 5. Kuo G, Choo Q-L, Alter H, et al. An assay for circulating antibodies to a major etiologic virus of human non-a, non-b hepatitis. Science 1989; 244: Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 15: Smith BD, Teshale E, Jewett A, et al. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 2011; 53: Hosseini-Moghaddam S, Iran-Pour E, Rotstein C, et al. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol [Epub ahead of print] 9. Barrera JM, Bruguera M, Ercilla MG, et al. Incidence of non-a, non-b hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers. Ann Intern Med 1991; 115: Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti- HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68: Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8: Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(RR-19): CDC. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR 2003; 52(RR-3): Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011; 204: Food and Drug Administration. Available at: fda.gov/scripts/cdrh/cfdocs/cfclia/detail.cfm?id= &noclia=1& pagenum=500. Accessed 15 April Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003; 7: Saldanha J, Heath A, Aberham C, et al.. World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sang 2005; 88: Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003; 7: Muerhoff AS, Jiang L, Shah DO, et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 2002; 42: Shah DO, Chang CD, Jiang LX, et al. Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer. Transfusion 2003; 43: Piccoli PL, Franchini M, Gandini G, et al. HCV core antigen assay. Transfusion 2001; 41: Azzazy HM, Mansour MM, Kazmierczak SC. Nanodiagnostics: a new frontier for clinical laboratory medicine. Clin Chem 2006; 52: Al Olaby RR, Azzazy HM. Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications. Expert Rev Mol Diagn 2011; 11: Roh C, Lee HY, Kim SE, Jo SK. A highly sensitive and selective viral protein detection method based on RNA oligonucleotide nanoparticle. Int J Nanomedicine 2010; 5: Klostranec JM, Xiang Q, Farcas GA, et al. Convergence of quantum dot barcodes with microfluidics and signal processing for multiplexed high-throughput infectious disease diagnostics. Nano Lett 2007; 7: Duan L, Wang Y, Li SS, Wan Z, Zhai J. Rapid and simultaneous detection of human hepatitis B virus and hepatitis C virus antibodies based on a protein chip assay using nano-gold immunological amplification and silver staining method. BMC Infect Dis 2005; 5: Shawky SM, Bald D, Azzazy HM. Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles. Clin Biochem 2010; 43: Shi H, Hoffman BE, Lis JT. RNA aptamers as effective protein antagonists in a multicellular organism. Proc Natl Acad Sci U S A 1999; 96: Tang J, Yu T, Guo L, Xie J, Shao N, He Z. In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection. Biosens Bioelectron 2007; 22: Chen F, Hu Y, Li D, Chen H, Zhang XL. CS-SELEX generates highaffinity ssdna aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 2009; 4:e Lee S, Kim YS, Jo M, Jin M, Lee DK, Kim S. Chip-based detection of hepatitis C virus using RNA aptamers that specifically bind to HCV core antigen. Biochem Biophys Res Commun 2007; 358: Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000; 28:E Mori Y, Nagamine K, Tomita N, Notomi T. Detection of loopmediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem Biophys Res Commun 2001; 289: Nagamine K, Hase T, Notomi T. Accelerated reaction by loopmediated isothermal amplification using loop primers. Mol Cell Probes 2002; 16: Fang X, Liu Y, Kong J, Jiang X. Loop-mediated isothermal amplification integrated on microfluidic chips for point-of-care quantitative detection of pathogens. Anal Chem 2010; 82: Lewis-Ximenez Lia L, Lauer Georg M, Schulze zur Wiesch J, et al. Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clinical Infectious Diseases 2010; 50: Quinti I, Hassan N, Salman D, et al. Hepatitis C virus-specific B cell activation: IgG and IgM detection in acute and chronic hepatitis C. Journal of Hepatology 1995; 23: McGovern Barbara H, Birch Christopher E, Bowen Melinda J, et al. Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria. Clinical Infectious Diseases 2009; 49: Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-hcv-igm titre and IgG Avidity Index. Journal of Clinical Virology 2009; 46: Ward K, Dhaliwall W, Ashworth K, Clutterbuck E, Teo C. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. Journal of Medical Virology 1994; 43: Kanno A, Kazuyama Y. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection. Journal of Medical Virology 2002; 68: Klimashevskaya S, Obriadina A, Ulanova T, et al. Distinguishing Acute from Chronic and Resolved Hepatitis C Virus (HCV) Infections by Measurement of Anti-HCV Immunoglobulin G Avidity Index. Journal of Clinical Microbiology 2007; 45: Araujo AC, Astrakhantseva IV, Fields HA, Kamili S. Distinguishing Acute from Chronic Hepatitis C Virus (HCV) Infection Based on Antibody Reactivities to Specific HCV Structural and Nonstructural Proteins. Journal of Clinical Microbiology 2010; 49:54 7. S48 CID 2012:55 (Suppl 1) Kamili et al

New HIV Tests and Algorithm: A change we can believe in

New HIV Tests and Algorithm: A change we can believe in New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be

More information

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests IBIMA Publishing Journal of Virology & Microbiology http://www.ibimapublishing.com/journals/jvm/jvm.html Vol. 2013 (2013), Article ID 332501, 7 pages DOI: 10.5171/2013.332501 Research Article Decision

More information

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016 New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new

More information

The Alphabet Soup of Viral Hepatitis Testing

The Alphabet Soup of Viral Hepatitis Testing The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,

More information

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves

More information

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages

More information

HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS

HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS I. Qattan Centres for Hepatology, Royal Free & University College Medical School, London V. Emery Department of Virology, Royal Free & University

More information

Diagnostic reliability of Architect anti- HCV assay: Experience of a tertiary care hospital in India

Diagnostic reliability of Architect anti- HCV assay: Experience of a tertiary care hospital in India Received: 3 February 2017 Accepted: 28 March 2017 DOI: 10.1002/jcla.22245 RESEARCH ARTICLE Diagnostic reliability of Architect anti- HCV assay: Experience of a tertiary care hospital in India Gnanadurai

More information

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC) HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC

More information

All you can use to diagnose HCV 4 th Annual Preceptorship EMERGING CHALLENGES IN THE MANAGEMENT OF CHRONIC LIVER DISEASE Berne 18 th May 2017

All you can use to diagnose HCV 4 th Annual Preceptorship EMERGING CHALLENGES IN THE MANAGEMENT OF CHRONIC LIVER DISEASE Berne 18 th May 2017 All you can use to diagnose HCV 4 th Annual Preceptorship EMERGING CHALLENGES IN THE MANAGEMENT OF CHRONIC LIVER DISEASE Berne 18 th May 2017 Francesco Negro University Hospital of Geneva, Switzerland

More information

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like

More information

Introduction to the Impact of Resistance in Hepatitis C

Introduction to the Impact of Resistance in Hepatitis C Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored

More information

Viral Hepatitis Diagnosis and Management

Viral Hepatitis Diagnosis and Management Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx 0244-055-00 OraQuick HCV Rapid Antibody Test Kit with product codes 1001-0270

More information

CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD

CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories

More information

Robert G. Gish MD UC San Diego

Robert G. Gish MD UC San Diego Robert G. Gish MD UC San Diego The Pipeline of HIV-Related Point-Of- Care Tests is Growing Viral detection Examples: 2012 2013 2014 2015 2016 2017 CD4 test Examples: 2009 2010 2011 2012 2013 0 2014 Evidence

More information

HIV Diagnostic Testing

HIV Diagnostic Testing In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk

More information

2018 HIV and HCV Diagnostic Testing Survey

2018 HIV and HCV Diagnostic Testing Survey 2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will

More information

Received 30 July 2011/Returned for modification 1 September 2011/Accepted 14 September 2011

Received 30 July 2011/Returned for modification 1 September 2011/Accepted 14 September 2011 JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2011, p. 4089 4093 Vol. 49, No. 12 0095-1137/11/$12.00 doi:10.1128/jcm.05292-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison

More information

Hepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...

Hepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re... Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional

More information

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What

More information

Utility of Virological Assays at the DAA Era

Utility of Virological Assays at the DAA Era Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital

More information

Anti-Infective Clinical Trials

Anti-Infective Clinical Trials Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting

More information

The Latest in HIV Tests: What Do the Results Mean?

The Latest in HIV Tests: What Do the Results Mean? The Latest in HIV Tests: What Do the Results Mean? Bernard M. Branson MD Principal Consultant, Scientific Affairs LLC Atlanta, Georgia Objectives At the end of this workshop, participants will be able

More information

HIV Testing Technology and the Latest Algorithm

HIV Testing Technology and the Latest Algorithm HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with

More information

Virology and Diagnosis of the Hepatitis C Virus

Virology and Diagnosis of the Hepatitis C Virus Virology and Diagnosis of the Hepatitis C Virus Final version, 18.04.2009 Mareike K.S. Richter Student number 1667238 Supervisors: H.G.M. Niesters, J.R. Lo Ten Foe 1 Index 1 Introduction 3 1.1 Classification

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test

More information

Diagnosis of Acute HCV Infection

Diagnosis of Acute HCV Infection Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson

More information

Review. Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection

Review. Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection Muhammad Amjad, PhD, 1* Varsha Moudgal, MD, 2 Muhammad Faisal, MD 3 ABSTRACT Hepatitis C virus (HCV) infection is associated

More information

Technical Bulletin No. 162

Technical Bulletin No. 162 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations

More information

A Summary of Clinical Evidence

A Summary of Clinical Evidence A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table

More information

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual 2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein

More information

Innovation in Diagnostics. ToRCH. A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES

Innovation in Diagnostics. ToRCH. A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES Innovation in Diagnostics ToRCH A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES EN TOXOPLASMOSIS Toxoplasmosis is a parasitic disease caused by with the obligate intracellular

More information

Laboratory and Clinical Diagnosis of HCV Infection

Laboratory and Clinical Diagnosis of HCV Infection Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests

More information

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation Alere (honoraria) List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

Virological Tools and Monitoring in the DAA Era

Virological Tools and Monitoring in the DAA Era Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital

More information

Complicated viral infections

Complicated viral infections Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western

More information

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha

More information

Overview of HIV Testing Practices and Technology

Overview of HIV Testing Practices and Technology Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease

More information

AccuVert HBV Seroconversion Panel PHM941(M) ( )

AccuVert HBV Seroconversion Panel PHM941(M) ( ) PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics

More information

HIV-1 Seroconversion Panel PRB973

HIV-1 Seroconversion Panel PRB973 A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians

More information

Documentation, Codebook, and Frequencies

Documentation, Codebook, and Frequencies 2 Documentation, Codebook, and Frequencies Laboratory Component: Hepatitis B: core antibody, surface antibody and surface antigen; Hepatitis C: confirmed antibody; Hepatitis D antibody Survey Years: 2003

More information

Hepatitis C Best Practice Guidelines For Local Health Departments

Hepatitis C Best Practice Guidelines For Local Health Departments Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have

More information

Diagnostic Tests for HIV

Diagnostic Tests for HIV Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,

More information

P0141 HBV 1000 copies/ml genotype reference panel

P0141 HBV 1000 copies/ml genotype reference panel P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents

More information

Rama Nada. - Malik

Rama Nada. - Malik - 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect

More information

AccuSet HCV Performance Panel

AccuSet HCV Performance Panel Signal to cutoff (s/co) DATA SHEET OVERVIEW AccuSet HCV (0810-0204) is a 25-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members

More information

Hepatitis C. Core slides

Hepatitis C. Core slides Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and

More information

on October 4, 2018 by guest

on October 4, 2018 by guest JCM Accepts, published online ahead of print on 3 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.01249-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Title: Performance of

More information

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere HIV Combo WHO reference number: PQDx 0243-013-00 Alere HIV Combo with product codes 7D2842, 7D2843, 7D2843SET manufactured by Alere

More information

AccuVert HIV-1 Seroconversion Panel PRB974 ( )

AccuVert HIV-1 Seroconversion Panel PRB974 ( ) PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers

More information

Feature. Downloaded from by guest on 06 November 2018

Feature. Downloaded from   by guest on 06 November 2018 Hepatitis C Virus: Epidemiology, Diagnosis, and Patient Management Peter P. Chou, PhD, DABCC, FACB (Quest Diagnostics Nichols Institute, Chantilly, VA) DOI: 10.1309/BNK8PH8FEPJ0VCH2 Laboratory photo courtesy

More information

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management

More information

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: HIV 1/2 STAT-PAK Number: PQDx Abstract

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: HIV 1/2 STAT-PAK Number: PQDx Abstract WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: HIV 1/2 STAT-PAK Number: PQDx 0007-006-00 Abstract The HIV 1/2 STAT-PAK with product code HIV101, manufactured by Chembio Diagnostic

More information

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the

More information

HIV-1 Seroconversion Panel

HIV-1 Seroconversion Panel A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The Seroconversion is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers

More information

HIV-1 Seroconversion Panel PRB975

HIV-1 Seroconversion Panel PRB975 Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,

More information

Point-of-care testing and other new diagnostics for HCV

Point-of-care testing and other new diagnostics for HCV Point-of-care testing and other new diagnostics for HCV Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie,

More information

Identification of Microbes Lecture: 12

Identification of Microbes Lecture: 12 Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected

More information

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere q HIV-1/2 Detect WHO reference number: PQDx 0226-032-00 Alere q HIV-1/2 Detect with product codes 270110050, 270110010 and 270300001,

More information

Sensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population

Sensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population JOURNAL OF CLINICAL MICROBIOLOGY, July 2002, p. 2387 2391 Vol. 40, No. 7 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.7.2387 2391.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hepatitis_c 1/1/2019 N/A 1/1/2020 1/1/2019 Description of Procedure or Service Description Hepatitis C is

More information

Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory

Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Describe the challenges in syphilis diagnostics Present two testing algorithms Non-treponemal test as initial screen Treponemal

More information

Clinical Performance Evaluation of Four Automated Chemiluminescence Immunoassays for Hepatitis C Virus Antibody Detection

Clinical Performance Evaluation of Four Automated Chemiluminescence Immunoassays for Hepatitis C Virus Antibody Detection JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2008, p. 3919 3923 Vol. 46, No. 12 0095-1137/08/$08.00 0 doi:10.1128/jcm.01603-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Clinical

More information

The Application of molecular POCT for Influenza and Group A Strep Detection

The Application of molecular POCT for Influenza and Group A Strep Detection The Application of molecular POCT for Influenza and Group A Strep Detection Gregory J. Berry, Ph.D., D(ABMM) Assistant Professor, Pathology and Laboratory Medicine Zucker School of Medicine at Hofstra/Northwell

More information

Hepatitis C in Australia:

Hepatitis C in Australia: Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated

More information

Comparison between ELISA and chemiluminescence immunoassay for the detection of Hepatitis C virus antibody

Comparison between ELISA and chemiluminescence immunoassay for the detection of Hepatitis C virus antibody Original Research Article DOI: 10.18231/2394-5478.2017.0078 Comparison between ELISA and chemiluminescence immunoassay for the detection of Hepatitis C virus antibody Pampi Majumder 1, Anup Kumar Shetty

More information

HEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)

HEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis) Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis

More information

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:

More information

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Murex HIV Ag/Ab Combination Number: PQDx 0144-043-00 Abstract Murex HIV Ag/Ab Combination with product codes 7G79-09 (GE41,

More information

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection

More information

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Some HCV History 1970s: many cases reported called non-a, non-b hepatitis

Some HCV History 1970s: many cases reported called non-a, non-b hepatitis Hepatitis C virus 1 Some HCV History 1970s: many cases reported called non-a, non-b hepatitis 1988: hepatitis C virus identified 1990: antibody screening tests available 1992: better tests to insure safety

More information

الحترمونا من خري الدعاء

الحترمونا من خري الدعاء الحترمونا من خري الدعاء Instructions for candidates The examination consists of 30 multiple choice questions, each divided into 5 different parts. Each part contains a statement which could be true or

More information

Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing?

Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing? Original Paper Received: September 1, 2015 Accepted: October 4, 2015 Published online: January 20, 2016 Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental

More information

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Hepatitis C: Progress and Problems

Hepatitis C: Progress and Problems CLINICAL MICROBIOLOGY REVIEWS, Oct. 1994, p. 505-532 0893-8512/94/$04.00+0 Copyright 1994, American Society for Microbiology Vol. 7, No. 4 Hepatitis C: Progress and Problems JENNIFER A. CUTHBERT* Liver

More information

Official Journal of the European Communities COMMISSION

Official Journal of the European Communities COMMISSION 16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under

More information

Hepatitis C Virus Diagnosis and Testing

Hepatitis C Virus Diagnosis and Testing Hepatitis C Virus Diagnosis and Testing Mel Krajden, MD, FRCPC Development of serological and nucleic acid testing (NAT) has revolutionized hepatitis C virus (HCV) diagnosis. Although third generation

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST

More information

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd

More information

Serology and International units

Serology and International units Serology and International units L. Grangeot-Keros, National Reference Laboratory for Rubella, Virology Department, A. Béclère Hospital, Clamart, France Detection of rubella-specific IgG antibody Assays

More information

WHO Parvovirus B19 Genotype Panel

WHO Parvovirus B19 Genotype Panel WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)

More information

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion

More information

Assays to Address Emerging Threats to Blood Safety

Assays to Address Emerging Threats to Blood Safety Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of

More information

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel signal to cut-off (s/co) DATA SHEET OVERVIEW PRB205(M3) is a modified 16-member panel originating from Anti- HIV-1 Mixed Titer PRB205(M2). Panel members 3, 5, 6, 17, 21, 22, 23, 24, and 25 from the original

More information

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our

More information

HBV PUBLIC HEALTH IMPLICATIONS

HBV PUBLIC HEALTH IMPLICATIONS جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.

More information

CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE

CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE TITLE : SOP for (off board dilution) Less Sensitive Modified VITROS Enzyme Immunoassay CEPHIA DOCUMENT

More information

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single

More information

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut

More information